Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT05874310
Recruiting Early Phase 1

Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa

NCT05874310 · tracked via the Priya Life Science China tracker
Sponsor
Frontera Therapeutics
Phase
Early Phase 1
Started
2023-02-01
Last updated
2023-05-24

Condition(s) studied

X-Linked Retinitis Pigmentosa

Investigational drug(s) / intervention(s)

FT-002

FT-002: Comparison of different dosages of FT-002

Study summary

A clinical trial of gene therapy for patients with X-linked retinitis pigmentosa (XLRP).

Eligibility

Sex
MALE
Min age
8 Years
Max age
45 Years
Healthy volunteers
No
Inclusion Criteria: 1.Subjects that are willing and able to follow study procedures; 2.Males aged 8-45 years old at the time of signing the Informed Consent Form; 4.Subjects who are confirmed with variants of RPGR ; Exclusion Criteria: 1.Have other retinal degenerative diseases, such as retinal degeneration caused by other known Inherited retinal disease gene variants or previously received an gene therapy product.

Primary outcome measure(s)

  • Incidence of AEs — from FT-002 administration through up to 1 years
    Number and proportion of Adverse Events

Trial sites (2)

FacilityCityRegionStatus
Peking Union Medical College Hospital Beijing Beijing Municipality Recruiting
Eye & ENT hospital of Fudan university Shanghai Shanghai Municipality Recruiting

More Frontera Therapeutics trials in China

Gene Therapy(FT-003) for Wet AMD Recruiting
Gene Therapy in Subjects With Biallelic RPE65 Mutation-associated Retinal Dystrophy Recruiting
Gene Therapy for Diabetic Macular Edema Recruiting
Gene Therapy for DME Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05874310 on ClinicalTrials.gov ↗ ← All trials in China